Nexus Oncology, a Scottish company specialising in cancer drug development services, has launched a growth and expansion programme, including a push into the US market, on the back of what it described as ‘outstanding’ results in its most recent financial year.
Nexus grew its turnover by over 50% to £2.5 million ($4.7m) during the financial year ending April 30 and says it has signed £5 million of new business during the first quarter of this year with new and existing clients.
Nexus conducts clinical trials for oncology treatments at leading cancer centres throughout Europe and will soon expand to include trials in the USA. It established a small presence in the USA in 2005 and will open an office there later this year.
The news comes as Clare Wareing, founder of Nexus, changes roles to become the company’s director of corporate development, charged with focusing on strategic growth and building and maintaining relationships with clients and cancer centres through out the world.
Wareing’s switch in roles gives Jane McCracken the post of chief exeutive. She has worked with Nexus as a consultant and member of its board of directors for the past 18 months. McCracken is based in the USA and will divide her time between there and the UK.
The management reshuffle also sees two new recruitments to Nexus – Irene Gow joins as director of scientific affairs, while Alan Bennie takes the role of finance director.
